New drug form of indapamid SR, or are all diuretics the same?;Nová lieková forma indapamidu SR, albebo sú všetky diuretiká rovnaké?

Kardiologia

Volumn 13, Issue 3, 2004, Pages 150-156

  Bada, Viliam ^a  

^a Katedry Vnutorneho Lekarstva   (Slovakia)

Author keywords

Arterial hypertension; Diuretics; Indapamid SR 1.5 mg

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAT; GLUCOSE; INDAPAMIDE; MAGNESIUM; PERINDOPRIL; POTASSIUM; SODIUM; SUGAR; URIC ACID;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED RELEASE FORMULATION; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPOPROTEINEMIA; FOOD AND DRUG ADMINISTRATION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INCIDENCE; LIPID METABOLISM; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; TABLET FORMULATION; VASODILATATION;

EID: 3042628881     PISSN: 12100048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-1504.
2. Sleight P. Current options in the management of coronary artery disease. Am J Cardiol 2003;92(Suppl.):4N-8N.
3. The Seventh report of the Joint national committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 report. JAMA 2003;289:2560-2572.
4. Saxl P, Heilig R. Über die diuretische wirkung von Novasurol und anderen quecksilberinjektionen. Wien Klin Wochenschr 1920;33:943-946.
5. Friedberg CK. Diseases of the heart. Third edition. Philadelphia, London: WB Saunders 1969:1787.
6. Schück O, Stříbrná J. Diuretika v terapii edémových stavů. Praha: SPOFA, Bratislava: OBZOR 1970:137.
7. Mann T, Keilin D. Sulphanilamide as a specific inhibitor of carbonic anhydrase. Nature 1940;146:164-168.
8. Schwartz W.: The effect of sulfanilamide on salt and water excretion in congestive heart failure. N Engl J Med 1949;240:173-179.
9. Avery's Drug Treatment. 4th Edition. Edited by Speight TM & Holford NHG. Auckland, Philadelphia, Sydney: Adis International Ltd. 1997:1852.
10. Prichard BNC, Owens CWI, Woolf AS. Adverse reactions to diuretics. Eur Heart J 1992;13 (Suppl. G):96-101.
11. Van Zwieten PA. Comparative mechanism of action of diuretic drugs in hypertension. Eur Heart J 1992;13(Suppl. G):2-8.
12. Hampton JR. Comparative efficacy of diuretics: benefits versus risks: results of clinical trials. Eur Heart J 1992;13(Suppl. G):85-90.
13. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. EWPHE Lancet 1985;i:1349-1354.
14. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
15. SHEP Cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
16. MRC Working Party Medical research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
17. Post-Stroke Antihypertensive Treatment Study (PATS) Collaborating group Post-Stroke Antihypertensive Treatment Study. Chinese Med J 1995;108:710-717.
18. PROGRESS Collaborative group Randomised trial of perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
19. Gorelick PB. New horizons in stroke prevention. PROGRESS and Hope 2002;1:149-156.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid lowering treatment to prevent heart attack trial ALLHAT. JAMA 2002;288:2981-2997.
21. Schück O. Studie ALLHAT-poznámky z pohledu nefrologa. JAMA-CS. Výber 2003;III:211-213.
22. Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled European studies. J Hypertens 1998;16:1677-1684.
23. Mallion JM, Asmar R, Boutelant S, et al. Twenty-Four Hour Antihypertensive Efficacy of Indapamide, 1.5-Mg Sustained Release: Results of Two Randomized Double-Blind Controlled Studies. J Cardiovasc Pharmacol 1998;32:673-678.
24. Jaillon P, Asmar R. Thirty-two-hour ambulatory blood pressure monitoring for the assessment of blood pressure evolution in case of a missed dose of indapamide SR 1.5 mg. J Hypertens 2001;19(Suppl. 2):S234-238.
25. Gosse P, Sheridan DJ, Zanad F, et al. Regression of the left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18:1465-1475.
26. Asmar R, Amah G, Grisan O, et al. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999;(Suppl. P):P21-30.
27. Weidmann P. Metabolic profile of indapamide sustained release in patients with hypertension. Data from three randomised double-blind studies. Drug Safety 2001;24:1155-1165.
28. Dzúrik R, Dzúriková V. Diuretická lieč ba. 2. vydanie. Martin: Osveta 1981:210.